In vitro activity of fenticonazole against Candida and bacterial vaginitis isolates determined by mono- Or dual-species testing assays

Maurizio Sanguinetti, Brunella Posteraro, Riccardo Torelli, Emilia Cantón, Fabio Tumietto, Ana Espinel-Ingroff

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We determined the in vitro activity of fenticonazole against 318 vaginitis isolates of Candida and bacterial species and selected 28 isolates for time-kill studies. At concentrations equal to 4 MIC, fenticonazole reached the 99.9% killing endpoint by 10 h for Staphylococcus aureus, Streptococcus agalactiae, and Escherichia coli and by 17 h for Candida albicans and Candida parapsilosis; and at concentrations equal to 8 MIC, by 19 and 20 h for Candida glabrata and Candida tropicalis, respectively. At concentrations equal to 2 MIC, fenticonazole required 20 h to reach the above endpoint against C. albicans in mixed culture with S. aureus, S. agalactiae, or E. coli versus 17 h against C. albicans in pure culture. Supra-MICs are achievable in topically treated patients’ vaginal surfaces.
Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalANTIMICROBIAL AGENTS AND CHEMOTHERAPY [CD-ROM]
Volume63
DOIs
Publication statusPublished - 2019

Keywords

  • Antimicrobial susceptibility testing
  • Fenticonazole
  • Targeted therapy
  • Vaginal isolates

Fingerprint

Dive into the research topics of 'In vitro activity of fenticonazole against Candida and bacterial vaginitis isolates determined by mono- Or dual-species testing assays'. Together they form a unique fingerprint.

Cite this